文献速递慢性肾脏病肾小球疾病

轻链淀粉样变性中肾脏生存期延长:轻链降低的速度与幅度是关键因素

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
PubMed 文献 · Kidney Int · 2017-07-18

该研究基于英国ALchemy前瞻性队列中84例eGFR<20 ml/min/1.73 m²的AL淀粉样变性合并晚期CKD患者,评估化疗后3、6、12个月时的血液学反应与肾脏结局的关系。结果显示,3个月内实现致病性游离轻链(dFLC)抑制≥90%的患者总生存、透析时间及「死亡或透析」复合终点均显著更优,且该反应是三个结局指标的唯─独立预测因素。

要点

  • 3个月内dFLC降低≥90%与更好的总生存、更晚透析及更优「死亡或透析」复合终点显著相关。
  • 即使达到≥90% dFLC反应但延迟超过3个月,结局仍较差。
  • 3个月内≥90% dFLC反应是三个结局指标的唯─显著独立预测因素。

核心结论

  • 在AL淀粉样变性合并晚期CKD患者中,肾脏生存强烈依赖于化疗抑制血液学克隆的速度和幅度。

研究设计与样本

  • 基于英国AL amyloidosis化疗研究(ALchemy)前瞻性队列,纳入1000例患者,其中84例为淀粉样变性相关晚期CKD(eGFR<20 ml/min/1.73 m²),中位eGFR为10 ml/min/1.73 m²。

主要发现

  • 3个月内dFLC抑制≥90%的患者较同期反应程度较低者总生存显著更优、透析时间显著延长、「死亡或透析」复合终点时间显著延长。
  • 达到≥90% dFLC反应但延迟超过3个月仍与更差结局相关。
  • Cox回归分析显示3个月内≥90% dFLC反应是总生存、透析时间及「死亡或透析」复合终点的唯─显著独立预测因素。

关键数值与推荐

  • 晚期淀粉样变性相关CKD定义为eGFR<20 ml/min/1.73 m²。
  • 血液学反应目标为3个月内dFLC抑制≥90%。

临床怎么用

  • 对AL淀粉样变性合并晚期CKD患者,应尽早启动化疗并以3个月内dFLC降低≥90%为血液学反应目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal involvement causing progressive chronic kidney disease (CKD) is present in 70% of patients with systemic Ig light-chain (AL) amyloidosis at diagnosis. Chemotherapy that substantially suppresses free light chain production is associated with improved patient survival, but its benefit in delaying the onset of renal replacement therapy among patients who present with established advanced CKD has not been studied. To evaluate this, we studied 1000 patients enrolled in the prospective UK AL amyloidosis chemotherapy study (ALchemy). Of these, 84 patients had advanced amyloid-related CKD defined by an estimated glomerular filtration rate (eGFR) under 20 ml/min/1.73 m2. We determined outcomes among these 84 patients, who had a median eGFR of 10 ml/min/1.73 m2, in relation to response to chemotherapy evaluated at three, six, and 12 months from baseline. Patients who achieved suppression of 90% or more in their amyloidogenic free light chain (dFLC) within three months of baseline had significantly better overall survival, prolonged time to dialysis, and prolonged time to the composite endpoint of 'death or dialysis' compared to those who achieved lesser degrees of clonal response at the same time point. Even when this target of greater than 90% dFLC response was achieved but was delayed beyond 3 months, it was associated with worse outcomes. Cox regression analyses confirmed that a 90% or better dFLC response within 3 months was the only significant independent predictor of all three of these outcome measures. Thus, renal survival among patients with systemic immunologic light chain amyloidosis who present with advanced CKD is strongly dependent upon the magnitude and speed with which the underlying hematologic disorder is suppressed by chemotherapy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Rezk T, Lachmann HJ, Fontana M, et al. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. Kidney Int. 2017. PMID: 28729034. doi:10.1016/j.kint.2017.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。